• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Giusti Kathryn E

    12/21/21 6:30:47 AM ET
    $CMLT
    Get the next $CMLT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    GIUSTI KATHRYN E

    (Last) (First) (Middle)
    EQRX, INC.
    50 HAMPSHIRE STREET

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    EQRx, Inc. [ EQRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/17/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $8.84 12/17/2021 A(1) 159,286 (1) 09/22/2031 Common Stock 159,286 $0.00 159,286 D
    Earn-out Shares (2) 12/17/2021 A(2) 21,820 (2) 12/17/2024 Common Stock 21,820 (2) 21,820 D
    Explanation of Responses:
    1. These options were issued under the 2019 Stock Option and Grant Plan (the "2019 Plan") of EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx") and were assumed upon the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and Legacy EQRx, pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. One-third of the shares underlying this option vest and become exercisable on the one-year anniversary of the vesting commencement date (September 21, 2022), with the remainder vesting in 24 equal monthly installments, subject to the Reporting Person continuous service as of each vesting date.
    2. Upon consummation of the Business Combination, the Reporting Person received the right to acquire 21,820 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 15,274 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 6,546 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement.
    Remarks:
    /s/ William Collins, Attorney-in-Fact 12/20/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMLT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices

    Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceedsCombined company to trade on Nasdaq Global Market under ticker "EQRX" NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (NASDAQ:CMLT, CMLTW, CMLTU))), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, and EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the completion of their business combination. The business combination was approved by CM Life S

    12/17/21 12:45:00 PM ET
    $CMLT

    $CMLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Casdin Eli acquired 8,659,372 shares, was granted 39,527,670 shares, converted options into 8,659,372 shares and disposed of 8,659,372 shares (Amendment)

    4/A - EQRx, Inc. (0001843762) (Issuer)

    12/23/21 8:47:17 PM ET
    $CMLT

    SEC Form 3: New insider Ah Equity Partners Lsv I, L.L.C. claimed ownership of 53,064,157 shares

    3 - EQRx, Inc. (0001843762) (Issuer)

    12/22/21 9:09:54 PM ET
    $CMLT

    SEC Form 3: New insider Ah Equity Partners Bio Ii, L.L.C. claimed ownership of 53,064,157 shares

    3 - EQRx, Inc. (0001843762) (Issuer)

    12/22/21 9:05:05 PM ET
    $CMLT

    $CMLT
    SEC Filings

    View All

    SEC Form EFFECT filed by CM Life Sciences III Inc.

    EFFECT - EQRx, Inc. (0001843762) (Filer)

    12/27/21 12:15:14 AM ET
    $CMLT

    SEC Form 424B3 filed by CM Life Sciences III Inc.

    424B3 - EQRx, Inc. (0001843762) (Filer)

    12/23/21 5:24:09 PM ET
    $CMLT

    SEC Form S-1 filed by CM Life Sciences III Inc.

    S-1 - EQRx, Inc. (0001843762) (Filer)

    12/20/21 9:17:41 PM ET
    $CMLT

    $CMLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CM Life Sciences III Inc.

    SC 13D - EQRx, Inc. (0001843762) (Subject)

    12/27/21 4:31:28 PM ET
    $CMLT

    SEC Form SC 13D filed by CM Life Sciences III Inc.

    SC 13D - EQRx, Inc. (0001843762) (Subject)

    12/27/21 4:15:17 PM ET
    $CMLT

    SEC Form SC 13G filed by CM Life Sciences III Inc.

    SC 13G - CM Life Sciences III Inc. (0001843762) (Subject)

    12/10/21 4:41:04 PM ET
    $CMLT